Saxenda (liraglutide)

What this page used to say

• 2026-09-13 — Saxenda's price. Was: $315 to $415 a month through telehealth. Now: No price shown: no seller on this site offers branded Saxenda at a published cash price.
• 2026-09-13 — Removed: Saxenda is tolerated less well than the weekly drugs. Was: A daily injection means the gastrointestinal effects arrive daily rather than weekly, which is one reason it is tolerated less well than the weekly drugs. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: In the adult trials 9.8% of people on Saxenda stopped because of side effects, against 4.3% on placebo, most often for nausea (2.9%), vomiting (1.7%) or diarrhea (1.4%). If a dose increase is not tolerated, the label says to consider waiting about one more week before the next one, which is a conversation with the prescriber rather than a reason to quit unannounced.
• 2026-09-13 — Who may stay on 2.4 mg of Saxenda. Was: The recommended dose. Escalation in children can take up to 8 weeks, and 2.4 mg is allowed if 3 mg is not tolerated. Now: The recommended dose. For adults the lower doses are for titration only: an adult who cannot tolerate 3 mg stops Saxenda. Children 12 and older who cannot tolerate 3 mg may drop to 2.4 mg, and stop if that is not tolerated either; their escalation can take up to 8 weeks.
• 2026-09-12 — Why Saxenda costs what it does. Was: The daily injection is the cost driver: a month is 30 doses rather than 4, which is why Saxenda rarely undercuts the weekly drugs even where its list price looks lower. Now: Hone Health, the one seller halfrx records, charges $315 to $415 a month, and the price rises with the dose: $315 at the starting dose and $415 at maintenance. At $415 Saxenda costs more than Wegovy's $349 direct from NovoCare. The 30 daily injections a month change how often you inject, not the monthly price.
• 2026-09-12 — Generic liraglutide: on sale, not entering the market. Was: Generic liraglutide is now entering the market, which will push the price below every branded alternative. Now: Generic liraglutide has been sold in the US since Teva launched generic Saxenda on 28 August 2025, so a branded Saxenda price is no longer the only liraglutide price.
• 2026-09-11 — A point in its favor that no longer stood. Was: Approved for adolescents aged 12 and over, where the newer agents have narrower labels. Now: Approved for adolescents aged 12 and over, as Wegovy and Qsymia are; Zepbound is for adults only.
• 2026-09-11 — A drawback that no longer stood. Was: At $315+ through telehealth it costs more than Calibrate charges for branded Wegovy, which works far better. Now: At $315 to $415 a month through telehealth it costs about what Wegovy does direct from NovoCare, $349, for roughly half the trial weight loss.
• 2026-09-10 — A price no page could confirm, ninety-two days old. Was: $315–$415, checked 2026-06-10. Now: $315–$415, checked 2026-08-19.
• 2026-09-05 — Changed the trial figure to the intention-to-treat result on the FDA label. Was: SCALE: about 8% mean weight loss over 56 weeks. Now: 7.4% — SCALE Obesity and Prediabetes, Study 1 on the label, 56 weeks: 7.4% mean weight loss on 3 mg against 3.0% on placebo, intention-to-treat.
• 2026-09-05 — Added the label warning against sharing a pen between patients. Was: The serious reactions list did not mention pen sharing. Now: Never share a pen between patients, even with a new needle (5.9) — sharing risks passing on blood-borne infection.
• 2026-09-05 — Removed a suicidality warning and a pregnancy contraindication the label no longer carries, and corrected the common reactions on the side-effects page. Was: Serious: 'Suicidal behavior and ideation'. Contraindications included 'Pregnancy'. Common included 'reduced appetite' and an unqualified 'low blood sugar'. Now: Serious: the label's current section 5 headings, which add severe gastrointestinal reactions, hypersensitivity and pulmonary aspiration. Contraindications: MTC or MEN 2 history, and serious hypersensitivity to liraglutide. Common: 'reduced appetite' removed; 'low blood sugar in people with type 2 diabetes'.
• 2026-09-05 — Added the label's restart rule to the missed-dose answer on the dosage page. Was: Saxenda is daily, so a missed dose is simply skipped — take the next one at the usual time, and do not double up. Now: A single missed dose is skipped. If more than 3 days have passed since the last injection, the label says to restart at 0.6 mg and repeat the weekly escalation; the Medication Guide says to call the prescriber about how to restart.

Every correction on this site, dated →